相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
Ronit Mazor et al.
ONCOTARGET (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
YAP Promotes Malignant Progression of Lkb1-Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin
Wenjing Zhang et al.
CANCER RESEARCH (2015)
MoFvAb: Modeling the Fv region of antibodies
Alexander Bujotzek et al.
MABS (2015)
Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
Ronit Mazor et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Advances in Anticancer Immunotoxin Therapy
Christine Alewine et al.
ONCOLOGIST (2015)
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
Anish Thomas et al.
ONCOTARGET (2015)
Targeting Bcl-2 stability to sensitize cells harboring oncogenic ras
Bo Peng et al.
ONCOTARGET (2015)
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
Emily Mason-Osann et al.
SCIENTIFIC REPORTS (2015)
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Ira Pastan et al.
CANCER RESEARCH (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Kevin Hollevoet et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Christine Alewine et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Despina Siolas et al.
CANCER RESEARCH (2013)
A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
John E. Weldon et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
Ronan J. Kelly et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
Wenhai Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake
Yujian Zhang et al.
CANCER RESEARCH (2010)
Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics
Satoshi Nagata et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
John E. Weldon et al.
BLOOD (2009)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
Iduna Fichtner et al.
CLINICAL CANCER RESEARCH (2008)
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The current state of serum biomarkers of hepatotoxicity
Josef Ozer et al.
TOXICOLOGY (2008)
Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome
Hao Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors
Yujian Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
Kei Kushitani et al.
PATHOLOGY INTERNATIONAL (2007)
Multiple comparisons and multiple contrasts in randomized dose-response trials-confidence interval oriented approaches
Ludwig A. Hothorn
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2006)
NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice
KA Mühlen et al.
JOURNAL OF IMMUNOLOGY (2004)
Value of mesothelin immunostaining in the diagnosis of mesothelioma
NG Ordóñez
MODERN PATHOLOGY (2003)
Inhibition of TNF-α produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2
M Onda et al.
JOURNAL OF IMMUNOLOGY (2000)
Importance of Kupffer cells for T-cell-dependent liver injury in mice
J Schümann et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
